Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.66 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9560112 | 0.85 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL9560036 | 0.83 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1NPSR1PLA2G4B | |
| SCHEMBL9560171 | 0.83 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1NPSR1PLA2G4B | |
| SCHEMBL9559867 | 0.83 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL10482299 | 0.80 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL10448487 | 0.79 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL9485399 | 0.77 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1ALDH1A1HPGDPTPN11 | |
| SCHEMBL10448298 | 0.76 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL10448473 | 0.74 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL3991652 | 0.73 | PTPN11 (0.67) | CYSLTR2CYSLTR1ALDH1A1HPGDPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0358240-B1 | INTERMEDIATES FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5034537-A | Alpha-methyl-4-halobenzenemethanamine salts of acids for cardiovascular disorders, respiratory system disorders and antiallergens | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| US-4939279-A | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | disclosed |
| EP-0358240-A2 | Intermediates for the preparation of leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |